BROOKLYN (CN) – Federal class actions in three states claim Bayer pushes its “Aspirin with Heart Advantage” with fraudulent claims that it prevents heart attacks. The FDA warned Bayer in October that it cannot advertise the drug for anything but pain relief.
Plaintiffs in Brooklyn demand $100 million in damages for a class of “hundreds of thousands.”
They say Bayer pushes the drug by claiming it can “help control cholesterol” and “can reduce heart risk attack by up to thirty percent.”
But the FDA has not tested aspirin for that, the plaintiffs say. In fact, the complaint alleges, the FDA warned Bayer in an Oct. 27 letter not to make the heart-related claims.
Similar class actions were filed in Newark and E. St. Louis Federal Courts.
The Newark plaintiffs are represented by David Cohen with Saltz Mongeluzzi.
The Illinois plaintiffs are represented by Mark Niemeyer with Onder Shelton.
The Brooklyn class is represented by Parker Waichman Alonso.